25 XP   0   0   10

Nanobiotix
Buy, Hold or Sell?

Let's analyse Nanobiotix together

PenkeI guess you are interested in Nanobiotix. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Nanobiotix. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Nanobiotix

I send you an email if I find something interesting about Nanobiotix.

Quick analysis of Nanobiotix (30 sec.)










What can you expect buying and holding a share of Nanobiotix? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$-0.62
Expected worth in 1 year
$-5.57
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-4.94
Return On Investment
-77.9%

For what price can you sell your share?

Current Price per Share
$6.35
Expected price per share
$6.05 - $7.99
How sure are you?
50%

1. Valuation of Nanobiotix (5 min.)




Live pricePrice per Share (EOD)

$6.35

Intrinsic Value Per Share

$-8.38 - $-2.76

Total Value Per Share

$-9.00 - $-3.38

2. Growth of Nanobiotix (5 min.)




Is Nanobiotix growing?

Current yearPrevious yearGrowGrow %
How rich?-$29.2m$28.9m-$58.2m-199.1%

How much money is Nanobiotix making?

Current yearPrevious yearGrowGrow %
Making money-$61.7m-$50.8m-$10.8m-17.6%
Net Profit Margin-1,194.4%-470,040.0%--

How much money comes from the company's main activities?

3. Financial Health of Nanobiotix (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#994 / 1031

Most Revenue
#350 / 1031

Most Profit
#947 / 1031

Most Efficient
#834 / 1031

What can you expect buying and holding a share of Nanobiotix? (5 min.)

Welcome investor! Nanobiotix's management wants to use your money to grow the business. In return you get a share of Nanobiotix.

What can you expect buying and holding a share of Nanobiotix?

First you should know what it really means to hold a share of Nanobiotix. And how you can make/lose money.

Speculation

The Price per Share of Nanobiotix is $6.35. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nanobiotix.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nanobiotix, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.62. Based on the TTM, the Book Value Change Per Share is $-1.24 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nanobiotix.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.31-20.6%-1.31-20.6%-1.08-17.0%-1.01-15.8%-0.69-10.9%
Usd Book Value Change Per Share-1.24-19.5%-1.24-19.5%-1.00-15.8%-0.33-5.1%-0.09-1.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.24-19.5%-1.24-19.5%-1.00-15.8%-0.33-5.1%-0.08-1.3%
Usd Price Per Share3.67-3.67-8.10-5.65-2.83-
Price to Earnings Ratio-2.80--2.80--7.50--6.34--3.17-
Price-to-Total Gains Ratio-2.97--2.97--8.08--0.37--0.37-
Price to Book Ratio-5.91--5.91-13.17-3.49-1.75-
Price-to-Total Gains Ratio-2.97--2.97--8.08--0.37--0.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.35
Number of shares157
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-1.24-0.33
Usd Total Gains Per Share-1.24-0.33
Gains per Quarter (157 shares)-194.06-51.16
Gains per Year (157 shares)-776.26-204.66
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-776-7860-205-215
20-1553-15620-409-420
30-2329-23380-614-625
40-3105-31140-819-830
50-3881-38900-1023-1035
60-4658-46660-1228-1240
70-5434-54420-1433-1445
80-6210-62180-1637-1650
90-6986-69940-1842-1855
100-7763-77700-2047-2060

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.012.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%6.06.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%1.00.09.010.0%2.00.010.016.7%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%6.06.00.050.0%

Fundamentals of Nanobiotix

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Fundamental data was last updated by Penke on 2024-03-21 00:56:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Nanobiotix.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Nanobiotix earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Nanobiotix to the Biotechnology industry mean.
  • A Net Profit Margin of -1,194.4% means that $-11.94 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nanobiotix:

  • The MRQ is -1,194.4%. The company is making a huge loss. -2
  • The TTM is -1,194.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,194.4%TTM-1,194.4%0.0%
TTM-1,194.4%YOY-470,040.0%+468,845.6%
TTM-1,194.4%5Y-127,825.6%+126,631.2%
5Y-127,825.6%10Y-66,270.3%-61,555.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,194.4%-171.8%-1,022.6%
TTM-1,194.4%-205.8%-988.6%
YOY-470,040.0%-262.1%-469,777.9%
5Y-127,825.6%-455.6%-127,370.0%
10Y-66,270.3%-589.0%-65,681.3%
1.1.2. Return on Assets

Shows how efficient Nanobiotix is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nanobiotix to the Biotechnology industry mean.
  • -95.4% Return on Assets means that Nanobiotix generated $-0.95 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nanobiotix:

  • The MRQ is -95.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -95.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-95.4%TTM-95.4%0.0%
TTM-95.4%YOY-46.2%-49.3%
TTM-95.4%5Y-64.4%-31.0%
5Y-64.4%10Y-63.9%-0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-95.4%-12.5%-82.9%
TTM-95.4%-12.2%-83.2%
YOY-46.2%-11.2%-35.0%
5Y-64.4%-13.4%-51.0%
10Y-63.9%-14.7%-49.2%
1.1.3. Return on Equity

Shows how efficient Nanobiotix is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nanobiotix to the Biotechnology industry mean.
  • 0.0% Return on Equity means Nanobiotix generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nanobiotix:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-175.5%+175.5%
TTM-5Y-86.6%+86.6%
5Y-86.6%10Y-101.5%+14.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.8%+15.8%
TTM--15.7%+15.7%
YOY-175.5%-13.9%-161.6%
5Y-86.6%-18.3%-68.3%
10Y-101.5%-19.2%-82.3%

1.2. Operating Efficiency of Nanobiotix.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Nanobiotix is operating .

  • Measures how much profit Nanobiotix makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nanobiotix to the Biotechnology industry mean.
  • An Operating Margin of -977.8% means the company generated $-9.78  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nanobiotix:

  • The MRQ is -977.8%. The company is operating very inefficient. -2
  • The TTM is -977.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-977.8%TTM-977.8%0.0%
TTM-977.8%YOY-525,790.0%+524,812.2%
TTM-977.8%5Y-138,867.3%+137,889.4%
5Y-138,867.3%10Y-71,780.6%-67,086.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-977.8%-299.1%-678.7%
TTM-977.8%-210.1%-767.7%
YOY-525,790.0%-279.7%-525,510.3%
5Y-138,867.3%-459.9%-138,407.4%
10Y-71,780.6%-596.9%-71,183.7%
1.2.2. Operating Ratio

Measures how efficient Nanobiotix is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 9.98 means that the operating costs are $9.98 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Nanobiotix:

  • The MRQ is 9.985. The company is inefficient in keeping operating costs low. -1
  • The TTM is 9.985. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ9.985TTM9.9850.000
TTM9.985YOY4,717.500-4,707.515
TTM9.9855Y1,281.444-1,271.459
5Y1,281.44410Y664.525+616.919
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.9852.861+7.124
TTM9.9853.193+6.792
YOY4,717.5003.615+4,713.885
5Y1,281.4445.560+1,275.884
10Y664.5257.396+657.129

1.3. Liquidity of Nanobiotix.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Nanobiotix is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.38 means the company has $1.38 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Nanobiotix:

  • The MRQ is 1.380. The company is just able to pay all its short-term debts.
  • The TTM is 1.380. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.380TTM1.3800.000
TTM1.380YOY2.526-1.146
TTM1.3805Y3.475-2.095
5Y3.47510Y3.967-0.492
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3803.986-2.606
TTM1.3804.440-3.060
YOY2.5265.552-3.026
5Y3.4756.158-2.683
10Y3.9676.492-2.525
1.3.2. Quick Ratio

Measures if Nanobiotix is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nanobiotix to the Biotechnology industry mean.
  • A Quick Ratio of 1.38 means the company can pay off $1.38 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nanobiotix:

  • The MRQ is 1.376. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.376. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.376TTM1.3760.000
TTM1.376YOY2.466-1.090
TTM1.3765Y3.383-2.007
5Y3.38310Y3.867-0.484
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3763.638-2.262
TTM1.3764.168-2.792
YOY2.4665.515-3.049
5Y3.3836.012-2.629
10Y3.8676.209-2.342

1.4. Solvency of Nanobiotix.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Nanobiotix assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nanobiotix to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.45 means that Nanobiotix assets are financed with 145.2% credit (debt) and the remaining percentage (100% - 145.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Nanobiotix:

  • The MRQ is 1.452. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.452. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.452TTM1.4520.000
TTM1.452YOY0.737+0.716
TTM1.4525Y0.878+0.575
5Y0.87810Y0.622+0.256
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4520.335+1.117
TTM1.4520.330+1.122
YOY0.7370.267+0.470
5Y0.8780.367+0.511
10Y0.6220.378+0.244
1.4.2. Debt to Equity Ratio

Measures if Nanobiotix is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nanobiotix to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nanobiotix:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY2.799-2.799
TTM-5Y1.189-1.189
5Y1.18910Y0.925+0.264
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.376-0.376
TTM-0.398-0.398
YOY2.7990.334+2.465
5Y1.1890.429+0.760
10Y0.9250.476+0.449

2. Market Valuation of Nanobiotix

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Nanobiotix generates.

  • Above 15 is considered overpriced but always compare Nanobiotix to the Biotechnology industry mean.
  • A PE ratio of -2.80 means the investor is paying $-2.80 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nanobiotix:

  • The EOD is -4.848. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.802. Based on the earnings, the company is expensive. -2
  • The TTM is -2.802. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.848MRQ-2.802-2.046
MRQ-2.802TTM-2.8020.000
TTM-2.802YOY-7.496+4.694
TTM-2.8025Y-6.338+3.536
5Y-6.33810Y-3.169-3.169
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.848-2.643-2.205
MRQ-2.802-2.418-0.384
TTM-2.802-2.742-0.060
YOY-7.496-4.123-3.373
5Y-6.338-6.257-0.081
10Y-3.169-6.478+3.309
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Nanobiotix:

  • The EOD is -7.435. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.297. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.297. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.435MRQ-4.297-3.138
MRQ-4.297TTM-4.2970.000
TTM-4.297YOY-11.718+7.421
TTM-4.2975Y-8.402+4.105
5Y-8.40210Y-4.201-4.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.435-3.244-4.191
MRQ-4.297-2.939-1.358
TTM-4.297-3.478-0.819
YOY-11.718-5.592-6.126
5Y-8.402-8.473+0.071
10Y-4.201-8.881+4.680
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Nanobiotix is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -5.91 means the investor is paying $-5.91 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Nanobiotix:

  • The EOD is -10.226. Based on the equity, the company is expensive. -2
  • The MRQ is -5.910. Based on the equity, the company is expensive. -2
  • The TTM is -5.910. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.226MRQ-5.910-4.316
MRQ-5.910TTM-5.9100.000
TTM-5.910YOY13.168-19.078
TTM-5.9105Y3.491-9.401
5Y3.49110Y1.746+1.746
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.2262.124-12.350
MRQ-5.9102.041-7.951
TTM-5.9102.118-8.028
YOY13.1682.915+10.253
5Y3.4913.682-0.191
10Y1.7464.114-2.368
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Nanobiotix.

3.1. Institutions holding Nanobiotix

Institutions are holding 19.683% of the shares of Nanobiotix.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Johnson & Johnson11.93730.933456238164664179486.0358
2023-12-31Baillie Gifford & Co Limited.6.08990.0166286903093283548.1788
2023-12-31Perceptive Advisors LLC1.17820.090255506600
2023-12-31BlackRock Inc0.463802185152185150
2023-12-31UBS Group AG0.006603100-706-18.5497
2023-12-31Citigroup Inc0.001306356350
2023-12-31Qube Research & Technologies0.00070343-357-51
2023-12-31Royal Bank of Canada0.000603053050
2023-12-31Morgan Stanley - Brokerage Accounts0.00060302-1398-82.2353
2023-12-31Bank of America Corp0.000301411410
2023-12-31Rhumbline Advisers0.000103300
2023-12-31Susquehanna International Group, LLP000-11201-100
2023-09-30JPMorgan Chase & Co000-2-100
2023-12-31Artal Group S A000-1000000-100
Total 19.67941.04029271286+4802946+51.8%

3.2. Funds holding Nanobiotix

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Baillie Gifford Global Discovery A Acc3.34781.54581577178198691.2759
2023-12-31Edinburgh Worldwide Ord2.84330.97051339532107480.8089
2024-02-29iShares Biotechnology ETF0.46970.0182221301-995-0.4476
2024-01-31Fidelity Nasdaq Composite Index0.01230.0003580900
Total 6.67312.53483143820+29622+0.9%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Nanobiotix compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.236-1.2360%-1.003-19%-0.326-74%-0.087-93%
Book Value Per Share---0.621-0.6210%0.615-201%0.379-264%0.443-240%
Current Ratio--1.3801.3800%2.526-45%3.475-60%3.967-65%
Debt To Asset Ratio--1.4521.4520%0.737+97%0.878+65%0.622+134%
Debt To Equity Ratio----0%2.799-100%1.189-100%0.925-100%
Dividend Per Share----0%-0%-0%0.002-100%
Eps---1.310-1.3100%-1.081-17%-1.005-23%-0.693-47%
Free Cash Flow Per Share---0.854-0.8540%-0.691-19%-0.753-12%-0.541-37%
Free Cash Flow To Equity Per Share---0.984-0.9840%-0.810-18%-0.031-97%0.077-1378%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---2.755--------
Intrinsic Value_10Y_min---8.380--------
Intrinsic Value_1Y_max---0.485--------
Intrinsic Value_1Y_min---0.783--------
Intrinsic Value_3Y_max---1.298--------
Intrinsic Value_3Y_min---2.416--------
Intrinsic Value_5Y_max---1.919--------
Intrinsic Value_5Y_min---4.105--------
Market Cap299156120.000+42%172898104.000172898104.0000%381600720.000-55%266366724.800-35%133183362.400+30%
Net Profit Margin---11.944-11.9440%-4700.400+39255%-1278.256+10602%-662.703+5449%
Operating Margin---9.778-9.7780%-5257.900+53670%-1388.673+14101%-717.806+7241%
Operating Ratio--9.9859.9850%4717.500-100%1281.444-99%664.525-98%
Pb Ratio-10.226-73%-5.910-5.9100%13.168-145%3.491-269%1.746-439%
Pe Ratio-4.848-73%-2.802-2.8020%-7.496+168%-6.338+126%-3.169+13%
Price Per Share6.350+42%3.6703.6700%8.100-55%5.654-35%2.827+30%
Price To Free Cash Flow Ratio-7.435-73%-4.297-4.2970%-11.718+173%-8.402+96%-4.201-2%
Price To Total Gains Ratio-5.137-73%-2.969-2.9690%-8.077+172%-0.372-87%-0.372-87%
Quick Ratio--1.3761.3760%2.466-44%3.383-59%3.867-64%
Return On Assets---0.954-0.9540%-0.462-52%-0.644-33%-0.639-33%
Return On Equity----0%-1.7550%-0.8660%-1.0150%
Total Gains Per Share---1.236-1.2360%-1.003-19%-0.326-74%-0.085-93%
Usd Book Value---29254576.500-29254576.5000%28978743.000-201%17858217.980-264%20874173.789-240%
Usd Book Value Change Per Share---1.236-1.2360%-1.003-19%-0.326-74%-0.087-93%
Usd Book Value Per Share---0.621-0.6210%0.615-201%0.379-264%0.443-240%
Usd Dividend Per Share----0%-0%-0%0.002-100%
Usd Eps---1.310-1.3100%-1.081-17%-1.005-23%-0.693-47%
Usd Free Cash Flow---40235994.900-40235994.9000%-32564578.500-19%-35490793.340-12%-25483062.003-37%
Usd Free Cash Flow Per Share---0.854-0.8540%-0.691-19%-0.753-12%-0.541-37%
Usd Free Cash Flow To Equity Per Share---0.984-0.9840%-0.810-18%-0.031-97%0.077-1378%
Usd Market Cap299156120.000+42%172898104.000172898104.0000%381600720.000-55%266366724.800-35%133183362.400+30%
Usd Price Per Share6.350+42%3.6703.6700%8.100-55%5.654-35%2.827+30%
Usd Profit---61703413.100-61703413.1000%-50844226.800-18%-47266179.540-23%-32581808.791-47%
Usd Revenue--5166199.2005166199.2000%10817.000+47660%1086026.800+376%892191.569+479%
Usd Total Gains Per Share---1.236-1.2360%-1.003-19%-0.326-74%-0.085-93%
 EOD+6 -2MRQTTM+0 -0YOY+8 -245Y+7 -2510Y+10 -24

4.2. Fundamental Score

Let's check the fundamental score of Nanobiotix based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.848
Price to Book Ratio (EOD)Between0-1-10.226
Net Profit Margin (MRQ)Greater than0-11.944
Operating Margin (MRQ)Greater than0-9.778
Quick Ratio (MRQ)Greater than11.376
Current Ratio (MRQ)Greater than11.380
Debt to Asset Ratio (MRQ)Less than11.452
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.954
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Nanobiotix based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.545
Ma 20Greater thanMa 506.454
Ma 50Greater thanMa 1006.960
Ma 100Greater thanMa 2006.664
OpenGreater thanClose6.150
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Other Assets  606-34572-2654615561-562-1
Depreciation and Amortization  7991,3682,1684,8367,0045,52612,530-18,047-5,517



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets59,769
Total Liabilities86,814
Total Stockholder Equity-27,045
 As reported
Total Liabilities 86,814
Total Stockholder Equity+ -27,045
Total Assets = 59,769

Assets

Total Assets59,769
Total Current Assets52,358
Long-term Assets7,412
Total Current Assets
Cash And Cash Equivalents 41,388
Short-term Investments 2,813
Net Receivables 7,988
Other Current Assets 1
Total Current Assets  (as reported)52,358
Total Current Assets  (calculated)52,190
+/- 168
Long-term Assets
Property Plant Equipment 7,120
Intangible Assets 1
Long-term Assets Other 291
Long-term Assets  (as reported)7,412
Long-term Assets  (calculated)7,412
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities37,936
Long-term Liabilities48,878
Total Stockholder Equity-27,045
Total Current Liabilities
Short-term Debt 4,560
Short Long Term Debt 3,598
Accounts payable 3,999
Other Current Liabilities 12,804
Total Current Liabilities  (as reported)37,936
Total Current Liabilities  (calculated)24,961
+/- 12,975
Long-term Liabilities
Long term Debt 44,040
Capital Lease Obligations 5,530
Other Liabilities 270
Long-term Liabilities  (as reported)48,878
Long-term Liabilities  (calculated)49,840
+/- 962
Total Stockholder Equity
Common Stock1,046
Retained Earnings -57,041
Accumulated Other Comprehensive Income -226,582
Other Stockholders Equity 255,532
Total Stockholder Equity (as reported)-27,045
Total Stockholder Equity (calculated)-27,045
+/-0
Other
Capital Stock1,046
Cash and Short Term Investments 41,388
Common Stock Shares Outstanding 34,852
Current Deferred Revenue16,573
Liabilities and Stockholders Equity 59,769
Net Debt 11,780
Net Invested Capital 20,593
Net Tangible Assets -27,046
Net Working Capital 14,422
Property Plant and Equipment Gross 15,300
Short Long Term Debt Total 53,168



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
> Total Assets 
2,913
14,024
7,439
37,054
26,418
30,403
57,467
46,195
56,205
134,030
101,769
59,769
59,769101,769134,03056,20546,19557,46730,40326,41837,0547,43914,0242,913
   > Total Current Assets 
2,333
13,539
6,894
35,505
22,948
26,890
53,109
42,651
46,127
125,248
93,060
52,358
52,35893,060125,24846,12742,65153,10926,89022,94835,5056,89413,5392,333
       Cash And Cash Equivalents 
899
12,361
5,002
32,986
17,003
21,058
47,212
36,203
35,094
119,151
83,921
41,388
41,38883,921119,15135,09436,20347,21221,05817,00332,9865,00212,361899
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
2,813
2,81300000000000
       Net Receivables 
1,347
1,071
1,693
2,044
4,737
5,028
4,897
5,352
8,363
3,880
6,926
7,988
7,9886,9263,8808,3635,3524,8975,0284,7372,0441,6931,0711,347
       Inventory 
88
-1,071
200
474
1,208
-5,028
-4,897
1,095
2,671
-40,320
-3,043
2,981
2,981-3,043-40,3202,6711,095-4,897-5,0281,208474200-1,07188
       Other Current Assets 
0
1,178
0
0
0
5,832
5,896
1
-1
42,537
5,256
1
15,25642,537-115,8965,8320001,1780
   > Long-term Assets 
580
485
545
1,549
3,470
3,512
4,358
3,544
10,078
8,782
8,709
7,412
7,4128,7098,78210,0783,5444,3583,5123,4701,549545485580
       Property Plant Equipment 
511
416
468
1,292
2,432
2,432
2,990
2,884
9,386
8,256
8,186
7,120
7,1208,1868,2569,3862,8842,9902,4322,4321,292468416511
       Long Term Investments 
0
0
0
0
0
0
0
176
131
105
98
0
0981051311760000000
       Intangible Assets 
7
0
9
10
8
4
136
102
163
21
4
1
14211631021364810907
       Long-term Assets Other 
63
69
68
247
0
0
0
382
-1
-1
421
291
291421-1-1382000247686963
> Total Liabilities 
1,988
3,328
4,257
6,738
10,807
13,004
13,545
31,952
58,114
63,562
74,979
86,814
86,81474,97963,56258,11431,95213,54513,00410,8076,7384,2573,3281,988
   > Total Current Liabilities 
1,415
2,160
3,282
4,424
7,102
8,246
9,351
11,597
14,347
19,041
36,845
37,936
37,93636,84519,04114,34711,5979,3518,2467,1024,4243,2822,1601,415
       Short-term Debt 
295
360
231
321
1,070
1,084
770
500
1,091
4,872
8,204
4,560
4,5608,2044,8721,0915007701,0841,070321231360295
       Short Long Term Debt 
0
0
0
0
0
1,084
770
500
500
3,674
7,078
3,598
3,5987,0783,6745005007701,08400000
       Accounts payable 
400
279
1,349
2,235
3,585
4,374
5,144
6,509
6,150
5,574
4,996
3,999
3,9994,9965,5746,1506,5095,1444,3743,5852,2351,349279400
       Other Current Liabilities 
0
0
662
438
658
556
474
4,588
1
1
7,127
12,804
12,8047,127114,58847455665843866200
   > Long-term Liabilities 
573
1,167
975
2,314
3,705
4,758
4,193
20,355
43,767
44,521
38,134
48,878
48,87838,13444,52143,76720,3554,1934,7583,7052,3149751,167573
       Other Liabilities 
0
0
0
0
0
175
234
334
331
414
318
270
27031841433133423417500000
> Total Stockholder Equity
926
10,697
3,182
30,315
15,611
17,398
43,922
14,243
-1,909
70,468
26,790
-27,045
-27,04526,79070,468-1,90914,24343,92217,39815,61130,3153,18210,697926
   Common Stock
230
323
323
422
425
479
589
589
672
1,033
1,045
1,046
1,0461,0451,033672589589479425422323323230
   Retained Earnings -57,041-47,003-33,590-50,915-30,345-26,143-21,881-17,003-9,557-8,145-5,331-5,247
   Capital Surplus 000000000000
   Treasury Stock000000000000
   Other Stockholders Equity 
6,584
16,486
11,852
40,398
33,333
40,320
71,330
122,675
152,970
255,539
255,564
255,532
255,532255,564255,539152,970122,67571,33040,32033,33340,39811,85216,4866,584



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue4,776
Cost of Revenue-985
Gross Profit3,7913,791
 
Operating Income (+$)
Gross Profit3,791
Operating Expense-46,703
Operating Income-46,702-42,912
 
Operating Expense (+$)
Research Development32,636
Selling General Administrative17,480
Selling And Marketing Expenses0
Operating Expense46,70350,116
 
Net Interest Income (+$)
Interest Income256
Interest Expense-5,837
Other Finance Cost-6,855
Net Interest Income-12,436
 
Pretax Income (+$)
Operating Income-46,702
Net Interest Income-12,436
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-57,033-36,371
EBIT - interestExpense = -52,539
-57,033
-51,206
Interest Expense5,837
Earnings Before Interest and Taxes (EBIT)-46,702-51,196
Earnings Before Interest and Taxes (EBITDA)-51,802
 
After tax Income (+$)
Income Before Tax-57,033
Tax Provision-10
Net Income From Continuing Ops-57,043-57,043
Net Income-57,043
Net Income Applicable To Common Shares-57,041
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses46,703
Total Other Income/Expenses Net-10,33112,436
 

Technical Analysis of Nanobiotix
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nanobiotix. The general trend of Nanobiotix is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nanobiotix's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Nanobiotix.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 7.13 < 7.19 < 7.99.

The bearish price targets are: 6.2 > 6.05 > 6.05.

Tweet this
Nanobiotix Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Nanobiotix. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Nanobiotix Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Nanobiotix. The current macd is -0.18658808.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Nanobiotix price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Nanobiotix. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Nanobiotix price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Nanobiotix Daily Moving Average Convergence/Divergence (MACD) ChartNanobiotix Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Nanobiotix. The current adx is 17.97.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Nanobiotix shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Nanobiotix Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Nanobiotix. The current sar is 6.98060103.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Nanobiotix Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Nanobiotix. The current rsi is 46.54. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Nanobiotix Daily Relative Strength Index (RSI) ChartNanobiotix Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Nanobiotix. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Nanobiotix price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Nanobiotix Daily Stochastic Oscillator ChartNanobiotix Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Nanobiotix. The current cci is -35.0755217.

Nanobiotix Daily Commodity Channel Index (CCI) ChartNanobiotix Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Nanobiotix. The current cmo is -4.38938724.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Nanobiotix Daily Chande Momentum Oscillator (CMO) ChartNanobiotix Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Nanobiotix. The current willr is -73.61318026.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Nanobiotix is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Nanobiotix Daily Williams %R ChartNanobiotix Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Nanobiotix.

Nanobiotix Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Nanobiotix. The current atr is 0.40613192.

Nanobiotix Daily Average True Range (ATR) ChartNanobiotix Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Nanobiotix. The current obv is 47,650,727.

Nanobiotix Daily On-Balance Volume (OBV) ChartNanobiotix Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Nanobiotix. The current mfi is 52.26.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Nanobiotix Daily Money Flow Index (MFI) ChartNanobiotix Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Nanobiotix.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-21ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Nanobiotix Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Nanobiotix based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.545
Ma 20Greater thanMa 506.454
Ma 50Greater thanMa 1006.960
Ma 100Greater thanMa 2006.664
OpenGreater thanClose6.150
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Nanobiotix with someone you think should read this too:
  • Are you bullish or bearish on Nanobiotix? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nanobiotix? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Nanobiotix

I send you an email if I find something interesting about Nanobiotix.


Comments

How you think about this?

Leave a comment

Stay informed about Nanobiotix.

Receive notifications about Nanobiotix in your mailbox!